AVAT-021

About Avata Biosciences

Avata Biosciences is a UK-based clinical-stage biotech leveraging a proprietary formulation technology to transform synthetic cannabinoids into water-soluble, solid-dose oral medicines. Its lead programs target significant unmet needs in adult and pediatric focal epilepsy and schizophrenia, with a strategy to utilize the FDA's 505(b)(2) regulatory pathway. The company is led by a seasoned team with deep experience from GW Pharmaceuticals and has established a key co-development partnership for the Asian market.

Therapeutic Areas